case 2: frontline therapy in egfr-mutated lung cancer
Published 5 years ago • 481 plays • Length 5:13Download video MP4
Download video MP3
Similar videos
-
3:09
case 2: osimertinib in egfr-mutated lung cancer
-
5:55
a case of egfr-mutant non–small cell lung cancer
-
5:00
case 2: testing for egfr in lung adenocarcinoma
-
6:59
case 2: diagnosing pd-l1 and egfr lung adenocarcinoma
-
0:48
current role of immunotherapy in egfr-mutant lung cancer
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies
-
20:24
targeted treatment with egfr tkis: front line options
-
3:06
exploring estrogen receptor roles and targeted therapy in nsclc
-
2:26
egfr mutations in nsclc
-
1:41
egfr mutations in patients with lung cancer
-
30:32
2023 best of lung: targeted therapies in lung cancer
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
1:23
flaura trial demonstrates efficacy in egfr-positive lung cancer
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
1:45
phase iii data support frontline osimertinib in egfr-mutant lung cancers
-
17:55
front-line targeted therapy for advanced egfr-positive disease
-
5:18
frontline therapy for egfr plus nsclc: osimertinib’s impact
-
1:44
dr. oxnard on delaying second-line treatment in egfr-mutant lung cancer
-
3:34
repeat biopsy in lung cancer patients with egfr mutation